Login to Your Account

Salix looks for smooth sailing to sNDA refiling for Xifaxan in IBS-D

By Marie Powers
Staff Writer

Tuesday, July 1, 2014
Shares of Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) got a boost Tuesday on word that a third phase III trial, TARGET 3, met its primary endpoint with statistical significance.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription